Trial · NCT01266083
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 24
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection Site Reaction | General disorders | Galinpepimut-S + Montanide + GM-CSF | 10 | 22 | |
| other | Skin Induration | Skin and subcutaneous tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 7 | 22 | |
| other | Fatigue | General disorders | Galinpepimut-S + Montanide + GM-CSF | 7 | 22 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 6 | 22 | |
| other | Lymphocyte Count Decreased | Investigations | Galinpepimut-S + Montanide + GM-CSF | 6 | 22 | |
| other | Neutrophil Count Decreased | Investigations | Galinpepimut-S + Montanide + GM-CSF | 6 | 22 | |
| other | White Blood Cell Count Decreased | Investigations | Galinpepimut-S + Montanide + GM-CSF | 6 | 22 | |
| other | Platelet Count Decreased | Investigations | Galinpepimut-S + Montanide + GM-CSF | 4 | 22 | |
| other | Pain | General disorders | Galinpepimut-S + Montanide + GM-CSF | 3 | 22 | |
| other | Erythema Multiforme | Skin and subcutaneous tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 3 | 22 | |
| other | Pain in Extremity | Musculoskeletal and connective tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 3 | 22 | |
| other | Flushing | Vascular disorders | Galinpepimut-S + Montanide + GM-CSF | 3 | 22 | |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 | |
| other | Rash Maculo-Papular | Skin and subcutaneous tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 | |
| other | Bone Pain | Musculoskeletal and connective tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 | |
| other | Muscular Weakness | Musculoskeletal and connective tissue disorders | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 | |
| other | Skin Infection | Infections and infestations | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 | |
| other | Urinary Tract Infection | Infections and infestations | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 | |
| other | Headache | Nervous system disorders | Galinpepimut-S + Montanide + GM-CSF | 2 | 22 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01266083/events